ALL KEYWORDS
Mature B-Cell Acute Lymphoblastic Leukemia
Related Specialists
Showing 3 of 34
Related Fact Sheets
Related Clinical Trials
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
- Leukemia & Hematologic Cancers
- Pediatric Cancers
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
- Lymphoma
- Leukemia & Hematologic Cancers
Related Departments
Showing 3 of 13